In Vivo Repair of a Protein Underlying a Neurological Disorder by Programmable RNA Editing
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Abstract RNA base editing is gaining momentum as an approach to repair mutations, but its application to neurological disease has not been established. We have succeeded in directed transcript editing of a pathological mutation in a mouse model of the neurodevelopmental disease, Rett syndrome. Specifically, we directed editing of a guanosine to adenosine mutation in RNA encoding Methyl CpG Binding Protein 2 (MECP2). Repair was mediated by injecting the hippocampus of juvenile Rett mice with an adeno-associated virus expressing both an engineered enzyme containing the catalytic domain of Adenosine Deaminase Acting on RNA 2 and a Mecp2 targeting guide. After one month, 50% of Mecp2 RNA was recoded in three different hippocampal neuronal subtypes, and the ability of MeCP2 protein to associate with heterochromatin was similarly restored to 50% of wild-type levels. This study represents the first in vivo programmable RNA editing applied to a model of neurological disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 1×
“Genomic and RNA base editing are potential therapeutic approaches for treating human disease (Gaudelli et al., 2017; Komor et al., 2016; Montiel-Gonzalez et al., 2019).”
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Regulation of serotonin-2C receptor G-protein coupling by RNA editing
Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., & Emeson, R. B. (1997) · Nature · doi:10.1038/387303a0 · Cited by 1,010 · cited 2×
“…treated as guanosine by the translational machinery (Basilio et al., 1962; Hoernes et al., 2018; Licht et al., 2019), resulting in codon changes with important consequences for protein function, particularly in the nervous system (Bhalla et al., 2004; Burns et al., 1997; Sommer et al., 1991).”
Neuronal MeCP2 Is Expressed at Near Histone-Octamer Levels and Globally Alters the Chromatin State
Skene, P. J., Illingworth, R. S., Webb, S., Kerr, A. R. W., James, K. D., Turner, D. J., Andrews, R., & Bird, A. P. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.030 · Cited by 688
Mild overexpression of MeCP2 causes a progressive neurological disorder in mice
Collins, A. L., Levenson, J. M., Vilaythong, A. P., Richman, R., Armstrong, D. L., Noebels, J. L., David Sweatt, J., & Zoghbi, H. Y. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh282 · Cited by 626
A role for glia in the progression of Rett’s syndrome
Lioy, D. T., Garg, S. K., Monaghan, C. E., Raber, J., Foust, K. D., Kaspar, B. K., Hirrlinger, P. G., Kirchhoff, F., Bissonnette, J. M., Ballas, N., et al. (2011) · Nature · doi:10.1038/nature10214 · Cited by 496 · cited 1×
“MeCP2 is expressed in most, if not all, neurons and glia (Ballas et al., 2009; Lioy et al., 2011; Rakela et al., 2018; Shahbazian et al., 2002; Skene et al., 2010), and previous studies have indicated that these cells can be targeted throughout the brain and spinal cord by adeno-associated virus 9…”
Self-citationNon–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology
Ballas, N., Lioy, D. T., Grunseich, C., & Mandel, G. (2009) · Nature Neuroscience · doi:10.1038/nn.2275 · Cited by 466
Self-citationIn vivo base editing of post-mitotic sensory cells
Yeh, W.-H., Chiang, H., Rees, H. A., Edge, A. S. B., & Liu, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-04580-3 · Cited by 225
Cited by
Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines
Liu, X., Zhang, Y., Zhou, S., Dain, L., Mei, L., & Zhu, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.043 · Cited by 366
RNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
Xiao, Q., Xu, Z., Xue, Y., Xu, C., Han, L., Liu, Y., Wang, F., Zhang, R., Han, S., Wang, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn0449 · Cited by 95
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
“MeCP2 is now considered a global regulator of chromatin structure that is required to fine-tune gene expression (Skene et al. 2010).”
BackgroundRNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Metadata
- Authors
- Sinnamon, J. R., Kim, S. Y., Fisk, J. R., Song, Z., Nakai, H., Jeng, S., McWeeney, S. K., & Mandel, G.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 32
- Issue
- 2
- Pages
- 107878
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3043502581
- Cited by
- 67
- References
- 11
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.